Onco360 Selected as Pharmacy Partner for Tibsovo and ORGOVYX®

Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company.

Servier Pharmaceuticals has chosen Onco360 to be a specialty pharmacy partner for Tibsovo (ivosidenib). Tibsovo is the first therapy targeting cancer metabolism for patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

AML is a difficult-to-treat cancer of the blood and bone marrow and is one of the most common types of leukemia in adults with about 20,000 new cases estimated in the United States each year. The IDH1 gene provides instructions for making the enzyme isocitrate dehydrogenase 1, which produces a molecule necessary for cellular processes. IDH1 mutations are present in about 6% to 10% of AML cases.

The FDA approved Tibsovo in May 2022 in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia. It is indicated for adults 75 years or older or those who are ineligible for intensive induction chemotherapy. It is also indicated to treat patients relapsed or refractory AML and locally advanced metastatic bile duct cancer. 

Earlier this year, Onco360 was selected by Myovant Sciences to be a specialty pharmacy partner for ORGOVYX^® (relugolix), which is a gonadotropin-releasing hormone (GnRH) antagonist that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced prostate cancer.

According to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, it is estimated that 268,490 new cases of prostate cancer will be diagnosed in 2022 with a corresponding 34,500 deaths as a result of the malignancy. Prostate cancer is the most commonly diagnosed cancer in male patients. The median age at the time of initial prostate cancer diagnosis is 67 years old with 92.5% of cases occurring in patients who are at least 55 years old.

Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies.

Takeaway: Onco360 is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company